Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy and rhGM-CSF for Metastatic NSCLC
NCT03113851Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2017
- Primary completion
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: The abscopal effect rate up to 50 months. Started Aug 2017; status: completed.
02
Drugs
sargramostim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03113851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113851.